Skip to content

Comparing the effectiveness and side effects of Avisirox and Nanojade in thalassemia patients

Comparative study of efficacy and side effects of Avisirox and Nanojade in thalassemia patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130812014333N227
Enrollment
190
Registered
2024-09-29
Start date
2024-10-06
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Beta thalassemia

Interventions

Intervention 1: In the first intervention group, Avisirox is prescribed to each patient daily at a dose of 40-20 mg/kg for 6 months. Intervention 2: In the second intervention group, each patient is p

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to No maximum

Inclusion criteria

Inclusion criteria: Thalassemia patients with ferritin greater than 500 Patients who need frequent blood transfusions Indication of receiving chelator At least 2 years old

Exclusion criteria

Exclusion criteria: History of liver and kidney failure History of high blood pressure, skin, respiratory and hearing diseases History of taking iron supplements

Design outcomes

Primary

MeasureTime frame
Respiratory complications. Timepoint: The beginning of the study, three and six months after the end of the study. Method of measurement: Asking the patient and doctor visits.;Skin complications. Timepoint: The beginning of the study, three and six months after the end of the study. Method of measurement: Asking the patient and doctor visits.;Digestive complications. Timepoint: The beginning of the study, three and six months after the end of the study. Method of measurement: Asking the patient and doctor visits.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Reza Golpaigani

Kermanshah University of Medical Sciences

mrgolpayegani@yahoo.com+98 83 3721 8202

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026